Seth Silber

Seth Silber

Wilson Sonsini Goodrich & Rosati

Contact
View Bio
RSS

Latest Posts › Hatch-Waxman

Share:

FTC Disputes Patent Listings of 10 Brand Drug Makers as Improperly Listed in FDA’s Orange Book

On November 7, 2023, the Federal Trade Commission (FTC) sent notice letters1 to 10 brand drug manufacturers of drug-device combination products, including drugs delivered by asthma inhalers, epinephrine autoinjectors, and...more

11/16/2023  /  Federal Trade Commission (FTC) , Food and Drug Administration (FDA) , FTC Act , Hatch-Waxman , Orange Book , Patent Infringement , Patents , Pharmaceutical Industry , Pharmaceutical Patents , Unfair Competition

FTC Workshop to Revisit Competition Issues Regarding Follow-On Biologics

Five years ago, the Federal Trade Commission (FTC) waded into the debate regarding the benefits and potential competition issues posed by the introduction of "follow-on biologics." Now, some three years after Congress...more

11/21/2013  /  Biologics , BPCIA , Competition , Federal Trade Commission (FTC) , Food and Drug Administration (FDA) , Hatch-Waxman , Pharmaceutical Industry , Prescription Drugs
2 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide